🇺🇸 FDA

Drug profile · INN

alirocumab

PRALUENT

approved C10AX14
US status
approved
Patents linked
2
News articles
0

Quick answer

alirocumab (PRALUENT) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN alirocumab
Brand PRALUENT
Route INJECTION
Formulation INJECTABLE
ATC code C10AX14
Originator Regeneron UK Limited

Related patents

Search patents →

  1. US 11904017

    Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10772956

    Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is alirocumab?

alirocumab (PRALUENT) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for alirocumab?

PRALUENT is a marketed brand name for alirocumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of alirocumab?

alirocumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.